Focus Partners Wealth’s UroGen Pharma URGN Stock Holding History

Focus Partners Wealth’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Sell	33,061 -977	-3%	-$26.5K	﹤0.01%	1567
2026 Q1	$612K	Sell	34,038 -1,239	-4%	-$24.8K	﹤0.01%	1830
2025 Q4	$826K	Buy	+35,277	New	+$765K	﹤0.01%	1720

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Focus Partners Wealth's URGN Position: Q2 2026 in Review

Focus Partners Wealth reduced its UroGen Pharma (URGN) stake by 2.9% in Q2 2026, selling an estimated $26.5K and leaving 33,061 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Focus Partners Wealth first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Focus Partners Wealth held 33,061 shares of UroGen Pharma worth $1.22M as of Q2 2026.
Focus Partners Wealth sold 977 UroGen Pharma shares in Q2 2026, an estimated $26.5K.
UroGen Pharma made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1567 holding.
Focus Partners Wealth first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.